Novocell garners $25M for stem cell work

San Diego-based Novocell--a stem cell engineering company--has raised $25 million in its third round of venture capital. Johnson & Johnson Development Corporation led the round and was joined by Sanderling Ventures, Asset Management Company and Pacific Horizon Ventures.

"Future milestones include the preclinical development of our diabetes cell therapy, enhancement of our cancer stem cell program to create new therapies for cancer and the development of additional cell therapies based on our significant know-how and research expertise in this arena," said Novocell CEO Alan J. Lewis.

- check out the release for more information

ALSO: Switzerland vaccine maker GlycoVaxyn has rounded up $9.3 million in its first round of venture capital. Sofinnova Partners and Index Ventures both increased their investment in the company after seeding the biotech in July 2006. The company is developing conjugated vaccines, which comprise an antigenic sugar residue and protein carrier (glycoproteins). Release

Related Articles:
Novocell scientists create insulin-producing cells. Report
Vaccine "renaissance" attracts huge new investments. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.